BRPI1013546A2 - usos de um inibidor da timidilato sintase e de uma terapia anticâncer - Google Patents

usos de um inibidor da timidilato sintase e de uma terapia anticâncer

Info

Publication number
BRPI1013546A2
BRPI1013546A2 BRPI1013546-4A BRPI1013546A BRPI1013546A2 BR PI1013546 A2 BRPI1013546 A2 BR PI1013546A2 BR PI1013546 A BRPI1013546 A BR PI1013546A BR PI1013546 A2 BRPI1013546 A2 BR PI1013546A2
Authority
BR
Brazil
Prior art keywords
synthase inhibitor
thymidylate synthase
cancer
therapy
anticancer therapy
Prior art date
Application number
BRPI1013546-4A
Other languages
English (en)
Portuguese (pt)
Inventor
W. Dawson David
K. Kurdistani Siavash
B. Seligson David
Original Assignee
The Regente Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regente Of The University Of California filed Critical The Regente Of The University Of California
Publication of BRPI1013546A2 publication Critical patent/BRPI1013546A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1013546-4A 2009-04-14 2010-04-14 usos de um inibidor da timidilato sintase e de uma terapia anticâncer BRPI1013546A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16921609P 2009-04-14 2009-04-14
US16921209P 2009-04-14 2009-04-14
US61/169216 2009-04-14
US61/169212 2009-04-14
US22516209P 2009-07-13 2009-07-13
US61/225162 2009-07-13
PCT/US2010/031112 WO2010120942A2 (en) 2009-04-14 2010-04-14 Histone modification patterns for clinical diagnosis and prognosis of cancer

Publications (1)

Publication Number Publication Date
BRPI1013546A2 true BRPI1013546A2 (pt) 2019-04-09

Family

ID=42983132

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013546-4A BRPI1013546A2 (pt) 2009-04-14 2010-04-14 usos de um inibidor da timidilato sintase e de uma terapia anticâncer

Country Status (8)

Country Link
US (1) US20120094949A1 (https=)
EP (1) EP2419737A4 (https=)
JP (1) JP2012524278A (https=)
CN (1) CN102460173A (https=)
AU (1) AU2010236415A1 (https=)
BR (1) BRPI1013546A2 (https=)
CA (1) CA2758933A1 (https=)
WO (1) WO2010120942A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
CN104067125B (zh) * 2011-12-07 2017-12-26 比利时意志有限责任公司 用于检测核小体加合物的方法
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
WO2015102536A1 (en) * 2013-12-30 2015-07-09 Agency For Science, Technology And Research Methods for measuring biomarkers in gastrointestinal cancer
JP2016044993A (ja) * 2014-08-20 2016-04-04 有限会社マイテック ヒストン化学修飾判定による癌診断方法
AU2015340378B2 (en) * 2014-10-29 2021-08-12 Belgian Volition Sprl Method for the enrichment of circulating tumor DNA
US10639349B2 (en) 2015-04-06 2020-05-05 The Johns Hopkins University H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
CA3033094A1 (en) * 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event
CN108957004B (zh) * 2018-07-09 2021-10-19 东南大学 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110221072B (zh) * 2019-06-10 2022-08-02 东南大学 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用
CN112904006B (zh) * 2021-01-28 2022-12-27 中山大学 一种乳腺癌预后预测分子标志物及其应用
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2024233383A1 (en) * 2023-05-05 2024-11-14 University Of Utah Research Foundation Systems and methods for point-of-care assessment based on pathology image analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
ATE489624T1 (de) * 2005-04-29 2010-12-15 Univ California Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
EP1937837A2 (en) * 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies

Also Published As

Publication number Publication date
WO2010120942A2 (en) 2010-10-21
EP2419737A4 (en) 2013-02-13
JP2012524278A (ja) 2012-10-11
WO2010120942A3 (en) 2011-02-24
US20120094949A1 (en) 2012-04-19
CA2758933A1 (en) 2010-10-21
AU2010236415A1 (en) 2011-12-01
EP2419737A2 (en) 2012-02-22
CN102460173A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
BRPI1013546A2 (pt) usos de um inibidor da timidilato sintase e de uma terapia anticâncer
Sun et al. Red light-emitting diode irradiation regulates oxidative stress and inflammation through SPHK1/NF-κB activation in human keratinocytes
NO20084546L (no) Diagnostikk og behandlinger for tumorer
BR112018073786A2 (pt) métodos e composições para tratamento de cânceres resistentes a inibidor da via de mapk não erk
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
BRPI0907637A8 (pt) biomarcadores p53
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2008018642A3 (en) Genes and polypeptides relating to breast cancers
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
AR098155A1 (es) Métodos para diagnosticar y tratar trastornos eosinofílicos
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
BR0211915A (pt) Execução de aplicação habilitada para teste
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
BR112015012536A2 (pt) tratamento de câncer com inibidores heterocíclicos da glutaminase
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
WO2008073629A3 (en) Bifunctional predictors of cancer treatment sensitivity and resistance
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]